RV-1729

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C39H39ClN8O5
Molecular Weight	735.231
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COCCN(CCOC)C(=O)CCCC#CC1=CC=CC2=C1C(=O)N(CC3=CC=CC=C3Cl)C(CN4N=C(C5=C4N=CN=C5N)C6=CC(O)=CC=C6)=N2

InChI

InChIKey=UBLOHCIYTDRGJH-UHFFFAOYSA-N

InChI=1S/C39H39ClN8O5/c1-52-20-18-46(19-21-53-2)33(50)17-5-3-4-10-26-12-9-16-31-34(26)39(51)47(23-28-11-6-7-15-30(28)40)32(44-31)24-48-38-35(37(41)42-25-43-38)36(45-48)27-13-8-14-29(49)22-27/h6-9,11-16,22,25,49H,3,5,17-21,23-24H2,1-2H3,(H2,41,42,43)

HIDE SMILES / InChI

Molecular Formula	C39H39ClN8O5
Molecular Weight	735.231
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
PI3-kinase p110-delta subunit 43 Target ID: CHEMBL3130 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24283201 \| https://adisinsight.springer.com/drugs/800037911	Inhibitor 8504		12.0 nM [IC50]
PI3-kinase p110-gamma subunit 32 Target ID: CHEMBL3267 Sources: https://adisinsight.springer.com/drugs/800037911 \| https://www.ncbi.nlm.nih.gov/pubmed/24283201 \| https://www.pharmacodia.com/yaodu/html/v1/chemicals/5c341d10c5596a0fd920fda9f33bcb06.html	Inhibitor 8504

Substance Class	Chemical Created by `admin` on `Tue Apr 01 18:46:17 GMT 2025` Edited by `admin` on `Tue Apr 01 18:46:17 GMT 2025`
Record UNII	06H865SCMW
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AZB 24987

Preferred Name

English

RV-1729

Code

English

5-HEXYNAMIDE, 6-(2-((4-AMINO-3-(3-HYDROXYPHENYL)-1H-PYRAZOLO(3,4-D)PYRIMIDIN-1-YL)METHYL)-3-((2-CHLOROPHENYL)METHYL)-3,4-DIHYDRO-4-OXO-5-QUINAZOLINYL)-N,N-BIS(2-METHOXYETHYL)-

Systematic Name

English

RV 1729

Code

English

RV1729

Code

English

6-(2-((4-AMINO-3-(3-HYDROXYPHENYL)-1H-PYRAZOLO(3,4-D)PYRIMIDIN-1-YL)METHYL)-3-((2-CHLOROPHENYL)METHYL)-3,4-DIHYDRO-4-OXO-5-QUINAZOLINYL)-N,N-BIS(2-METHOXYETHYL)-5-HEXYNAMIDE

Systematic Name

English

AZB-24987

Code

English

Code System Code Type Description

PUBCHEM

52913198

Created by admin on Tue Apr 01 18:46:17 GMT 2025 , Edited by admin on Tue Apr 01 18:46:17 GMT 2025

PRIMARY

CAS

1293915-42-0

Created by admin on Tue Apr 01 18:46:17 GMT 2025 , Edited by admin on Tue Apr 01 18:46:17 GMT 2025

PRIMARY

FDA UNII

06H865SCMW

Created by admin on Tue Apr 01 18:46:17 GMT 2025 , Edited by admin on Tue Apr 01 18:46:17 GMT 2025

PRIMARY

Related Record Type Details


					40QZG29AA4

PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT DELTA ISOFORM

TARGET -> INHIBITOR

Qualification:

IC50

Amount:


					1C47E5QIN2

PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT GAMMA ISOFORM

TARGET -> INHIBITOR

Qualification:

IC50

Amount:

Related Record Type Details


					06H865SCMW

RV-1729

ACTIVE MOIETY

Comments:

Originator: RespiVert; Class: Anti-inflammatory, Antiasthmatic, Bronchodilator, Small molecule; Mechanism of Action: Phosphatidylinositol 3 kinase delta inhibitor, Phosphatidylinositol 3 kinase gamma inhibitor; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phases: Phase I for Chronic obstructive pulmonary disease, No development reported for Asthma; Most Recent Events: 16 Jul 2016 No recent reports of development identified for phase-I development in Asthma in United Kingdom (Inhalation), 01 Jul 2015 RespiVert completes a phase I trial in Chronic obstructive pulmonary disease in United Kingdom (NCT02140346), 01 Mar 2015 RespiVert completes a phase I trial in Asthma in United Kingdom (NCT02140320)

Amount: